blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2253615

EP2253615 - Cyclopropyl amide derivatives [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.05.2015
Database last updated on 25.09.2024
Most recent event   Tooltip15.07.2016Lapse of the patent in a contracting state
New state(s): LU, TR		published on 17.08.2016  [2016/33]
Applicant(s)For all designated states
AstraZeneca AB
151 85 Södertälje / SE
[2014/28]
Former [2010/47]For all designated states
AstraZeneca AB
151 85 Södertälje / SE
Inventor(s)01 / Arnold, James
96 Toledo Way, Apartment 305
San Francisco, CA 94123 / US
02 / Edwards, Phil
1921 Marlboro Road
Kenneth Square, PA 19348 / US
03 / Griffin, Andrew
AstraZeneca R&D Montreal
7171 Frederick-Banting
Ville St. Laurent
Montreal Québec H4S 1Z9 / CA
04 / Groblewski, Thierry
AstraZeneca R&D Montreal
7171 Frédérick-Banting
St Laurent Québec H4S 1Z9 / CA
05 / Labrecque, Denis
AstraZeneca R&D Montreal
7171 Frederick-Banting
St. Laurent Québec H4S 1Z9 / CA
06 / Throner, Scott
AstraZeneca R&D Wilmington
P.O. Box 15437
1800 Concord Pike
Wilmington, DE 19850-5437 / US
07 / Wesolowski, Steven
AstraZeneca Wilmington
P.O. Box 15437 1800 Concord Pike
Wilmington, DE 19850-5437 / US
08 / Brugel, Todd Andrew
1800 Concord Pike P.O. Box 15437
Wilmington, DE 19850-5437 / US
09 / Brown, Dean
AstraZeneca R&D Boston
35 Gatehouse Drive
Waltham, Massachusetts 02451 / US
 [2014/28]
Former [2011/16]01 / Arnold, James
96 Toledo Way, Apartment 305
San Francisco, CA 94123 / US
02 / Edwards, Phil
1921 Marlboro Road
Kenneth Square, PA 19348 / US
03 / Griffin, Andrew
AstraZeneca R&D Montreal 7171 Frederick-Banting Ville St. Laurent
Montreal Québec H4S 1Z9 / CA
04 / Groblewski, Thierry
AstraZeneca R&D Montreal 7171 Frédérick-Banting
St Laurent Québec H4S 1Z9 / CA
05 / Labrecque, Denis
AstraZeneca R&D Montreal 7171 Frederick-Banting
St. Laurent Québec H4S 1Z9 / CA
06 / Throner, Scott
AstraZeneca R&D Wilmington P.O. Box 15437 1800 Concord Pike
Wilmington, DE 19850-5437 / US
07 / Wesolowski, Steven
AstraZeneca Wilmington P.O. Box 15437 1800 Concord Pike
Wilmington, DE 19850-5437 / US
08 / Brugel, Todd Andrew
1800 Concord Pike P.O. Box 15437
Wilmington, DE 19850-5437 / US
09 / Brown, Dean
AstraZeneca R&D Boston 35 Gatehouse Drive
Waltham, Massachusetts 02451 / US
Former [2010/50]01 / Arnold, James
96 Toledo Way, Apartment 305
San Francisco, CA 94123 / US
02 / Edwards, Phil
c/o AstraZeneca Intellectual Property AstraZeneca R&D Wilmington 1800 Concord Pike PO Box 15437
Wilmington, DE 19850-5437 / US
03 / Griffin, Andrew
AstraZeneca R&D Montreal 7171 Frederick-Banting Ville St. Laurent
Montreal Québec H4S 1Z9 / CA
04 / Groblewski, Thierry
AstraZeneca R&D Montreal 7171 Frédérick-Banting
St Laurent Québec H4S 1Z9 / CA
05 / Labrecque, Denis
AstraZeneca R&D Montreal 7171 Frederick-Banting
St. Laurent Québec H4S 1Z9 / CA
06 / Throner, Scott
AstraZeneca R&D Wilmington P.O. Box 15437 1800 Concord Pike
Wilmington, DE 19850-5437 / US
07 / Wesolowski, Steven
AstraZeneca Wilmington P.O. Box 15437 1800 Concord Pike
Wilmington, DE 19850-5437 / US
08 / Brugel, Todd Andrew
1800 Concord Pike P.O. Box 15437
Wilmington, DE 19850-5437 / US
Former [2010/47]01 / Arnold, James
96 Toledo Way, Apartment 305
San Francisco, CA 94123 / US
02 / Edwards, Philip
c/o AstraZenca Intellectual Property AstraZeneca R&D Wilmington 1800 Concord Pike PO Box 15437
Wilmington, DE 19850-5437 / US
03 / Griffin, Andrew
AstraZeneca R&D Montreal 7171 Frederick-Banting Ville St. Laurent
Montreal Québec H4S 1Z9 / CA
04 / Groblewski, Thierry
AstraZeneca R&D Montreal 7171 Frédérick-Banting
St Laurent Québec H4S 1Z9 / CA
05 / Labrecque, Denis
AstraZeneca R&D Montreal 7171 Frederick-Banting
St. Laurent Québec H4S 1Z9 / CA
06 / Throner, Scott
AstraZeneca R&D Wilmington P.O. Box 15437 1800 Concord Pike
Wilmington, DE 19850-5437 / US
07 / Wesolowski, Steven
AstraZeneca Wilmington P.O. Box 15437 1800 Concord Pike
Wilmington, DE 19850-5437 / US
08 / Brugel, Todd Andrew
1800 Concord Pike P.O. Box 15437
Wilmington, DE 19850-5437 / US
Representative(s)Curran, Clair, et al
Ropes & Gray International LLP
5 New Street Square
London EC4A 3BF / GB
[2013/46]
Application number, filing date10165133.920.08.2008
[2010/47]
Priority number, dateUS20070957181P22.08.2007         Original published format: US 957181 P
[2010/47]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2253615
Date:24.11.2010
Language:EN
[2010/47]
Type: B1 Patent specification 
No.:EP2253615
Date:09.07.2014
Language:EN
[2014/28]
Search report(s)(Supplementary) European search report - dispatched on:EP25.10.2010
ClassificationIPC:C07D211/40, C07D207/12, C07D295/18
[2010/47]
CPC:
A61K31/496 (EP,US); A61K31/495 (EP,US); A61K31/551 (EP,US);
A61P25/00 (EP); A61P25/02 (EP); A61P25/04 (EP);
A61P25/08 (EP); A61P25/18 (EP); A61P25/22 (EP);
A61P25/28 (EP); A61P29/00 (EP); A61P3/04 (EP);
A61P43/00 (EP); C07D207/12 (EP,US); C07D207/27 (EP,US);
C07D211/40 (EP,US); C07D211/76 (EP,US); C07D213/56 (EP,US);
C07D231/12 (EP,US); C07D233/36 (EP,US); C07D239/26 (EP,US);
C07D243/08 (EP,US); C07D295/18 (EP,US); C07D295/182 (EP,US);
C07D295/185 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/47]
Extension statesAL24.05.2011
BA24.05.2011
MK24.05.2011
RS24.05.2011
TitleGerman:Cyclopropylamidderivate[2010/47]
English:Cyclopropyl amide derivatives[2010/47]
French:Derives de cyclopropyl amide[2010/47]
Examination procedure07.06.2010Examination requested  [2010/47]
16.11.2010Despatch of a communication from the examining division (Time limit: M04)
04.03.2011Reply to a communication from the examining division
11.04.2012Despatch of a communication from the examining division (Time limit: M06)
11.10.2012Reply to a communication from the examining division
06.12.2013Communication of intention to grant the patent
03.04.2014Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
17.04.2014Communication of intention to grant the patent
27.05.2014Fee for grant paid
27.05.2014Fee for publishing/printing paid
27.05.2014Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP08788694.1  / EP2195293
Divisional application(s)EP14173061.4  / EP2805937
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20080788694) is  04.05.2012
Opposition(s)10.04.2015No opposition filed within time limit [2015/25]
Fees paidRenewal fee
07.10.2010Renewal fee patent year 03
31.08.2011Renewal fee patent year 04
31.08.2012Renewal fee patent year 05
02.09.2013Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU20.08.2008
AT09.07.2014
BE09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
MT09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
SE09.07.2014
SI09.07.2014
SK09.07.2014
TR09.07.2014
IE20.08.2014
LU20.08.2014
CH31.08.2014
LI31.08.2014
FR09.09.2014
BG09.10.2014
GB09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
DE03.03.2015
[2016/33]
Former [2016/32]HU20.08.2008
AT09.07.2014
BE09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
MT09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
SE09.07.2014
SI09.07.2014
SK09.07.2014
IE20.08.2014
CH31.08.2014
LI31.08.2014
FR09.09.2014
BG09.10.2014
GB09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
DE03.03.2015
Former [2016/28]AT09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
MT09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
SE09.07.2014
SI09.07.2014
SK09.07.2014
IE20.08.2014
BE31.08.2014
CH31.08.2014
LI31.08.2014
FR09.09.2014
BG09.10.2014
GB09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
DE03.03.2015
Former [2015/50]AT09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
SE09.07.2014
SI09.07.2014
SK09.07.2014
IE20.08.2014
BE31.08.2014
CH31.08.2014
LI31.08.2014
FR09.09.2014
BG09.10.2014
GB09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
DE03.03.2015
Former [2015/38]AT09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
SE09.07.2014
SK09.07.2014
IE20.08.2014
BE31.08.2014
CH31.08.2014
LI31.08.2014
FR09.09.2014
BG09.10.2014
GB09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
DE03.03.2015
Former [2015/37]AT09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
SE09.07.2014
SK09.07.2014
IE20.08.2014
BE31.08.2014
CH31.08.2014
LI31.08.2014
BG09.10.2014
GB09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
DE03.03.2015
Former [2015/36]AT09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
SE09.07.2014
SK09.07.2014
BE31.08.2014
CH31.08.2014
LI31.08.2014
BG09.10.2014
GB09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
DE03.03.2015
Former [2015/35]AT09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
SE09.07.2014
SK09.07.2014
BE31.08.2014
CH31.08.2014
LI31.08.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
DE03.03.2015
Former [2015/23]AT09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
SE09.07.2014
SK09.07.2014
BE31.08.2014
CH31.08.2014
LI31.08.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/22]AT09.07.2014
CY09.07.2014
DK09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
SE09.07.2014
BE31.08.2014
CH31.08.2014
LI31.08.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/20]AT09.07.2014
CY09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
NL09.07.2014
PL09.07.2014
SE09.07.2014
BE31.08.2014
CH31.08.2014
LI31.08.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/19]AT09.07.2014
CY09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
LT09.07.2014
LV09.07.2014
NL09.07.2014
PL09.07.2014
SE09.07.2014
BE31.08.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/12]AT09.07.2014
CY09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
LT09.07.2014
LV09.07.2014
NL09.07.2014
PL09.07.2014
SE09.07.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/11]CY09.07.2014
ES09.07.2014
FI09.07.2014
LT09.07.2014
PL09.07.2014
SE09.07.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
PT10.11.2014
Former [2015/10]ES09.07.2014
FI09.07.2014
LT09.07.2014
SE09.07.2014
BG09.10.2014
NO09.10.2014
Former [2015/09]FI09.07.2014
LT09.07.2014
SE09.07.2014
Former [2015/08]LT09.07.2014
Documents cited:Search[A]WO0040572  (NEUROGEN CORP [US], et al) [A] 1-13 * example - *;
 [A]US6284761  (ZHANG XIAOYAN [US], et al) [A] 1-13 * example - *;
 [A]  - KAZUYA YAMAGUCHI ET AL, "Construction of a cis-Cyclopropane via Reductive Radical Decarboxylation. Enantioselective Synthesis of cis- and trans-1-Arylpiperazyl-2-phenylcyclopropanes Designed as Antidopaminergic Agents", JOC, (2003), vol. 68, no. 24, pages 9255 - 9262, XP002512742 [A] 1-13 * example - *

DOI:   http://dx.doi.org/10.1021/JO0302206
 [A]  - XIAOYAN ZHANG, "trans-1-[(2-Phenylcyclopropyl)methyl]-4-arylpiperazines: mixed dopamine D2/D4 receptor antagonists as potential antipsychotic agents", J.MED.CHEM., (2000), vol. 43, no. 21, pages 3923 - 3932, XP002512743 [A] 1-13 * page 3924 - page 3929; examples 5w,x,y,z; table 1 *

DOI:   http://dx.doi.org/10.1021/JM990562X
by applicant   - ZARAGOZA, J MED. CHEM., (2004), vol. 47, pages 2833 - 2838
    - GILLASPY, TETRAHEDRON LETT., (1995), vol. 36, no. 41, pages 7399 - 7402
    - LEE, C.; YANG, W.; PARR, R. G., PHYS. REV. B, (1988), vol. 37, page 785
    - HARIHARAN, P.C.; POPLE, J.A., THEOR. CHIM. ACTA, (1973), vol. 28, page 213
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.